AstraZeneca plc's (LON:AZN) "Buy" Rating Reaffirmed at Deutsche Bank AG

AstraZeneca PLC (NYSE:AZN) is gaining traction with investors, as evidenced by its 3.25 million shares volume. Its last month's stock price volatility remained 1.21% which for the week stands at 1.54%. The stock has a 50 day moving average price of GBX 4,863.89 and a 200 day moving average price of GBX 4,868.98. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. Intrust Bank Na who had been investing in Astrazeneca Plc for a number of months, seems to be less bullish one the $73.30B market cap company. Shore Capital reissued a "sell" rating on shares of AstraZeneca plc in a report on Sunday, April 2nd. The company reported $0.87 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to analysts' expectations of $5.04 billion. However it has a net margin of 17.80%. The firm's revenue for the quarter was down 9.9% compared to the same quarter past year. During the same quarter previous year, the company posted $0.83 EPS. Equities analysts anticipate that Astrazeneca PLC will post $1.85 earnings per share for the current year.

The business also recently announced a None dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be paid a GBX 68.90 ($0.89) dividend. (AMG) Ex-Dividend Date Scheduled for August 08 ..." on August 07, 2017, also Nasdaq.com with their article: "Why Affiliated Managers (AMG) Q2 Earnings Might Disappoint" published on July 28, 2017, Nasdaq.com published: "Ex-Dividend Reminder: "Entergy, AmeriGas Partners and Affiliated Managers Group" on August 04, 2017. The company achieved year to date performance of 6.52% and disseminated yield of -1.82% for the past six months. The short ratio of stock is 3.66.AstraZeneca PLC (AZN) is a part of Healthcare sector and belongs to Drug Manufacturers - Major industry. Credit Suisse Group upgraded Astrazeneca PLC from an "underperform" rating to a "neutral" rating in a research report on Friday, May 12th. Barclays Capital upgraded it to "Equal-Weight" rating and $50 target in Tuesday, January 19 report. Deutsche Bank AG cut their price target on shares of AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,350 ($69.45) and set a buy rating on the stock in a report on Friday, April 28th.

Commercial Vehicle Group, Inc.is a supplier of a range of cab-related products and systems. (The) restated a "sell" rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of "Hold" and a consensus target price of $33.39.

Bristol Advisors LLC continued to hold its stake in shares of Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. Hudock Capital Group LLC boosted its position in shares of Astrazeneca PLC by 0.4% in the first quarter. The share last price represents downtick move of -18.37% in value from company's 52-Week high price and shows 13.74% above change in value from its 52-Week low price. Astrazeneca PLC makes up approximately 1.3% of First Bank & Trust's portfolio, making the stock its 21st largest position. Beacon Investment Advisory Services Inc. now owns 7,571 shares of the company's stock worth $236,000 after buying an additional 54 shares during the period. Nationwide Fund Advisors raised its stake in shares of Astrazeneca PLC by 3.8% in the first quarter. The stock was bought at an average price of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51).

COPYRIGHT VIOLATION NOTICE: This piece was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and worldwide trademark & copyright law.

Related News: